Literature DB >> 11882028

IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer.

J Riemensberger1, A Böhle, S Brandau.   

Abstract

In recent studies, a crucial role for IFN-gamma in immunosurveillance of tumours and in IL-12 immunotherapy has been suggested. Nevertheless, little is known about the relevance of IFN-gamma and IL-12 for tumour surveillance in noncytokine immunotherapy. Adjuvant immunotherapy with viable BCG (Bacillus Calmette--Guérin) is considered to be the most powerful clinical treatment regimen of bladder cancer and is known to induce a variety of proinflammatory cytokines. Consequently, we analysed the antitumour response of IFN-gamma knockout (KO), IL-12 KO and IL-10 KO mice in the absence and presence of BCG immunotherapy in a syngeneic orthotopic model of bladder cancer. IFN-gamma KO and IL-12 KO mice died much earlier and by far smaller tumour inocula compared to wildtype mice, while this intrinsic antitumour response was not altered in IL-10 KO mice. BCG immunotherapy was effective in wildtype mice, but totally ineffective in IFN-gamma KO and IL-12 KO mice. BCG induced a massive local immune response in the bladder of treated animals. This response was markedly increased in IL-10 KO mice, which coincides with increased therapeutic efficacy in this mouse strain compared with wildtype mice. Our data establish a crucial role for a Th1 type immune response in the intrinsic and immunotherapeutic control of local orthotopic bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882028      PMCID: PMC1906285          DOI: 10.1046/j.1365-2249.2002.01734.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  40 in total

Review 1.  Role of animal models in understanding intravesical therapy with bacille Calmette-Guérin.

Authors:  T L Ratliff
Journal:  Clin Infect Dis       Date:  2000-09       Impact factor: 9.079

2.  IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity.

Authors:  V Shankaran; H Ikeda; A T Bruce; J M White; P E Swanson; L J Old; R D Schreiber
Journal:  Nature       Date:  2001-04-26       Impact factor: 49.962

3.  Essential role of nitric oxide and interferon-gamma for tumor immunotherapy with interleukin-10.

Authors:  H Sun; P Gutierrez; M J Jackson; N Kundu; A M Fulton
Journal:  J Immunother       Date:  2000 Mar-Apr       Impact factor: 4.456

4.  Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity.

Authors:  Y Luo; X Chen; R Han; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2001-02       Impact factor: 4.330

5.  Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis.

Authors:  S E Street; E Cretney; M J Smyth
Journal:  Blood       Date:  2001-01-01       Impact factor: 22.113

6.  What are the immunologically active components of bacille Calmette-Guérin in therapy of superficial bladder cancer?

Authors:  A R Zlotta; J P Van Vooren; O Denis; A Drowart; M Daffé; P Lefèvre; L Schandene; M De Cock; J De Bruyn; P Vandenbussche; F Jurion; K Palfliet; J Simon; C C Schulman; J Content; K Huygen
Journal:  Int J Cancer       Date:  2000-09-15       Impact factor: 7.396

7.  Murine IL-2 secreting recombinant Bacillus Calmette-Guerin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2.

Authors:  H Yamada; S Matsumoto; T Matsumoto; T Yamada; U Yamashita
Journal:  J Urol       Date:  2000-08       Impact factor: 7.450

8.  Tumor-specific CD4(+) suppressor T-cell clone capable of inhibiting rejection of syngeneic sarcoma in A/J mice.

Authors:  T Fu; Y Shen; S Fujimoto
Journal:  Int J Cancer       Date:  2000-09-01       Impact factor: 7.396

9.  T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function.

Authors:  S Sharma; M Stolina; Y Lin; B Gardner; P W Miller; M Kronenberg; S M Dubinett
Journal:  J Immunol       Date:  1999-11-01       Impact factor: 5.422

10.  NK cells are essential for effective BCG immunotherapy.

Authors:  S Brandau; J Riemensberger; M Jacobsen; D Kemp; W Zhao; X Zhao; D Jocham; T L Ratliff; A Böhle
Journal:  Int J Cancer       Date:  2001-06-01       Impact factor: 7.396

View more
  33 in total

Review 1.  [Effect mechanism of intravesical BCG immunotherapy of superficial bladder cancer].

Authors:  A Böhle; H Suttmann; S Brandau
Journal:  Urologe A       Date:  2006-05       Impact factor: 0.639

2.  Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12.

Authors:  David A Zaharoff; Benjamin S Hoffman; H Brooks Hooper; Compton J Benjamin; Kiranpreet K Khurana; Kenneth W Hance; Connie J Rogers; Peter A Pinto; Jeffrey Schlom; John W Greiner
Journal:  Cancer Res       Date:  2009-07-28       Impact factor: 12.701

Review 3.  Evolving immunotherapy strategies in urothelial cancer.

Authors:  Sam J Brancato; Keidren Lewi; Piyush K Agarwal
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

Review 4.  Novel immunotherapeutic approaches to the treatment of urothelial carcinoma.

Authors:  Akhil Muthigi; Arvin K George; Sam J Brancato; Piyush K Agarwal
Journal:  Ther Adv Urol       Date:  2016-02-09

5.  Bacterial immunotherapy for cancer induces CD4-dependent tumor-specific immunity through tumor-intrinsic interferon-γ signaling.

Authors:  Anthony C Antonelli; Anna Binyamin; Tobias M Hohl; Michael S Glickman; Gil Redelman-Sidi
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-17       Impact factor: 11.205

6.  Bacillus Calmette Guerin induces fibroblast activation both directly and through macrophages in a mouse bladder cancer model.

Authors:  Catalina Lodillinsky; Yanina Langle; Ariel Guionet; Adrián Góngora; Alberto Baldi; Eduardo O Sandes; Alberto Casabé; Ana María Eiján
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

Review 7.  Mycobacterium bovis bacillus Calmette-Guérin-induced macrophage cytotoxicity against bladder cancer cells.

Authors:  Yi Luo; Matthew J Knudson
Journal:  Clin Dev Immunol       Date:  2010-09-01

8.  Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augments Th1 immunity and macrophage cytotoxicity.

Authors:  Y Luo; H Yamada; X Chen; A A Ryan; D P Evanoff; J A Triccas; M A O'Donnell
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

9.  Expression of chemokine/cytokine genes and immune cell recruitment following the instillation of Mycobacterium bovis, bacillus Calmette-Guérin or Lactobacillus rhamnosus strain GG in the healthy murine bladder.

Authors:  Shih Wee Seow; Juwita N Rahmat; Boon Huat Bay; Yuan Kun Lee; Ratha Mahendran
Journal:  Immunology       Date:  2008-01-22       Impact factor: 7.397

10.  Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model.

Authors:  Daher C Chade; Ricardo C Borra; Ivan P Nascimento; Fabiola E Villanova; Luciana C C Leite; Enrico Andrade; Miguel Srougi; Kátia L Ramos; Priscila M Andrade
Journal:  J Exp Clin Cancer Res       Date:  2008-11-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.